Status
Conditions
Treatments
About
The evidence on the effects of clinical care with cerebral NIRS (Near-infrared spectroscopy) monitoring on short term neurological outcome, displayed by fidgety movements between six to 20 weeks post term, are still uncertain.
Two centers (Graz and Innsbruck), who participated in the COSGOD III trial, routinely performed GMA between 37+0 to 42+0 weeks of corrected age (writhing movements) and between six to 20 weeks post term (fidgety movements).
Aim of the present study is therefore to assess in neonates, who were included into the COSGOD III trial, in a retrospective observational study routinely performed fidgety movements between six to 20 weeks of corrected age after discharge.
The investigators hypothesise that the preterm neonates in the intervention group of the COSGOD III trial show better survival and short term neurological outcome, displayed by normal fidgety movements, compared to neonates in the control group.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
183 participants in 2 patient groups
Loading...
Central trial contact
Gerhard Pichler, Prof; Christina H. Wolfsberger, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal